Calliditas Therapeutics AB
CIK 0001795579
Revenue (TTM)
—
Q2 Jun 2024
Net Income (TTM)
−538.89M
−13.1% YoY
Q2 Jun 2024
EPS Diluted (TTM)
−10.16
−11.7% YoY
Q2 Jun 2024
Gross Margin
—
Q2 Jun 2024
Operating Margin
—
Q2 Jun 2024
Net Margin
—
Q2 Jun 2024
Free Cash Flow (TTM)
—
Q2 Jun 2024
Cash
797.28M
Q2 Jun 2024
Total Debt
—
Q2 Jun 2024
Shares Outstanding
59.58M sh
Q2 Jun 2024
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.